Advancing a Bold Spectrum of Novel Therapies

Our pipeline spans a wide range of conditions, and includes several candidates that have advanced to clinical testing.

Diverse Indications

Our most advanced programs address disease areas of significant clinical interest.

Disease Area Clinical POC* Platform Discovery Early Clinical Late Clinical
Rare genetic disorders    
 
     
 
     
 
     
 
     
 
     
 
Metabolic disease    
 
   
 
Oncology    
 
     
 
Opportunistic
& multi-drug
resistant pathogens
   
 
     
 
Disease Area Clinical POC* Platform Discovery Early Clinical Late Clinical
Rare genetic disorders    
 
     
 
     
 
     
 
     
 
     
 
Metabolic disease    
 
   
 
Oncology    
 
     
 
Opportunistic
& multi-drug
resistant pathogens
   
 
     
 

Reduced Time to Clinic

Two key aspects of our strategy enable Kaleido to bring products to the clinic on a shorter timeline compared with traditional drug development efforts.

Our compound library includes sources of chemistry predominantly found in foods, significantly reducing safety concerns.

Our R&D engine makes it possible to study the human microbiome directly in a laboratory setting, which streamlines and accelerates the assessment of patient responses and inter-individual variability.